| Literature DB >> 26047144 |
Onno M Mets1, Suzan M Roothaan2, Inez Bronsveld3, Bart Luijk3, Ed A van de Graaf3, Aryan Vink2, Pim A de Jong1.
Abstract
BACKGROUND: Lung disease in cystic fibrosis (CF) involves excessive inflammation, repetitive infections and development of bronchiectasis. Recently, literature on emphysema in CF has emerged, which might become an increasingly important disease component due to the increased life expectancy. The purpose of this study was to assess the presence and extent of emphysema in endstage CF lungs.Entities:
Mesh:
Year: 2015 PMID: 26047144 PMCID: PMC4457847 DOI: 10.1371/journal.pone.0128062
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Examples of emphysema in the explanted lungs (H&E stained slides, magnification 200x).
A-E: Emphysematous changes in patients with CF. A = score 1: some emphysematous changes are present next to a scar in <20% of residual lung tissue. B-D = score 2: emphysematous changes in 20–50% of residual lung tissue, next to scar tissue (B) or in the paraseptal region (C and D). E = Score 3: emphysematous changes in >50% of residual lung tissue. F = Emphysema in an explanted lung of a patient with severe COPD, for comparison.
Fig 2Pre-transplant axial CT image of CF patient in the work-up to lung transplantation.
Both lungs show substantial apical bullous emphysema (panel A), automatically quantified (panel B) as 17,9% (IN-950). Histopathologically this case was assigned score 2 (20–50% emphysema in the residual lung tissue).
Clinical data of the study population.
| Case | Sex | Age | Genotype | Pancreatic status | CFRD | Pseudomonas colonization | CT quantified Lung volume (L) | CT Emphysema (IN-950, %) | FEV1 (%pred) | FEV1/FVC (%pred) | MEF25–75 (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 30,8 | F508del/F508del | Exocrine insufficiency | Yes | Yes | 4,80 | 10,3 | 21% | 46% | 5% |
| 2 | F | 34,3 | F508del/F508del | Exocrine insufficiency | Yes | Yes | 4,88 | 15,8 | 22% | 43% | 7% |
| 3 | M | 37,0 |
| Normal | No | Yes | 5,49 | 10,6 | 35% | 43% | 6% |
| 4 | M | 44,0 | F508del/3272-26 A>G | Normal | No | Yes | 4,66 | 10,4 | 24% | 58% | 9% |
| 5 | F | 20,5 |
| Exocrine insufficiency | Yes | Yes | 4,32 | 2,7 | 22% | 65% | 7% |
| 6 | M | 44,0 |
| Exocrine insufficiency | No | Yes | 5,81 | 11,3 | 18% | 47% | 6% |
| 7 | M | 31,5 | F508del/F508del | Exocrine insufficiency | Yes | Yes | 7,16 | 8,6 | 18% | 24% | 5% |
| 8 | F | 27,4 | F508del/F508del | Exocrine insufficiency | Yes | Yes | 3,57 | 8,9 | 23% | 68% | 10% |
| 9 | M | 32,2 | F508del/F508del | Exocrine insufficiency | Yes | Yes | 7,37 | 7,6 | 22% | 45% | 6% |
| 10 | M | 38,4 | F508del/A445E | Exocrine insufficiency | No | Yes | 5,95 | 5,2 | 25% | 51% | 6% |
| 11 | M | 35,6 | F508del/R553X | Exocrine insufficiency | Yes | Yes | 6,97 | 4,8 | 26% | 41% | 7% |
| 12 | F | 31,7 | F508del/F508del | Exocrine insufficiency | Yes | Yes | 5,06 | 10,8 | 24% | 54% | 8% |
| 13 | F | 27,8 | F508del/F508del | Exocrine insufficiency | Yes | Yes | 6,56 | 17,7 | 21% | 35% | 5% |
| 14 | M | 53,8 | R347P/4382delA | Exocrine insufficiency | No | Yes | 8,68 | 16,5 | 21% | 27% | 5% |
| 15 | M | 21,8 | F508del/F508del | Exocrine insufficiency | No | Yes | 6,92 | 5,1 | 15% | 49% | 5% |
| 16 | F | 48,6 | F508del//R1162X | Normal | No | Yes | 4,89 | 17,9 | 24% | 51% | 6% |
| 17 | M | 22,5 | F508del/F508del | Exocrine insufficiency | Yes | Yes | 5,99 | 5,7 | 20% | 61% | 5% |
| 18 | V | 16,2 | F508del/R1162X | Exocrine insufficiency | No | Yes | 4,75 | 1,2 | 29% | 63% | 12% |
| 19 | V | 53,1 | F508del/3272-26 A>G | Normal | No | No | 8,11 | 7,5 | 22% | 35% | 6% |
| 20 | M | 28,8 |
| Exocrine insufficiency | No | Yes | 4,99 | 16 | 20% | 58% | 8% |
| All | - | 32.0 (27.5–42.6) | - | 80% | 50% | 95% | 5.65 (4.85–6.96) | 9.5 (5.3–14.7) | 22% (20%-24%) | 48% (42%-58%) | 6% (5%-8%) |
Total values are presented as median with interquartile range.
* Missing data (4 cases)
a percentage with exocrine insufficiency
b percentage with CFRD
c percentage with pseudomonas colonization
IN CT emphysema quantified as the percentage of voxels below -950HU in inspiration
FEV Forced expiratory volume in the first second; FEV /FVC ratio of FEV1 over forced vital capacity; MEF Mean flow between 25% and 75% of forced vital capacity; CFRD cystic fibrosis related diabetes.
Visual grading of structural CF lung disease.
| Case | BE | %BE | MP | %MP | PBT | %PBT | PAR | %PAR | EMPH | %EMPH | Total | %Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 36 | 50 | 12 | 33 | 30 | 56 | 2 | 6 | 9 | 25 | 79 | 34 |
|
| 49 | 68 | 12 | 33 | 15 | 28 | 7 | 19 | 0 | 0 | 73 | 31 |
|
| 36 | 50 | 24 | 67 | 20 | 37 | 3 | 8 | 4 | 11 | 67 | 29 |
|
| 36 | 50 | 24 | 67 | 38 | 69 | 7 | 19 | 8 | 22 | 93 | 40 |
|
| 65 | 90 | 18 | 50 | 29 | 54 | 3 | 8 | 0 | 0 | 101 | 43 |
|
| 31 | 43 | 12 | 33 | 26 | 48 | 4 | 11 | 5 | 14 | 68 | 29 |
|
| 32 | 44 | 20 | 56 | 30 | 56 | 6 | 17 | 6 | 17 | 77 | 33 |
|
| 52 | 72 | 24 | 67 | 30 | 56 | 9 | 25 | 2 | 6 | 97 | 42 |
|
| 29 | 40 | 12 | 33 | 19 | 34 | 6 | 17 | 9 | 25 | 64 | 27 |
|
| 48 | 67 | 18 | 50 | 23 | 42 | 3 | 8 | 3 | 8 | 80 | 34 |
|
| 36 | 50 | 6 | 17 | 23 | 42 | 3 | 8 | 2 | 6 | 65 | 28 |
|
| 34 | 47 | 10 | 28 | 20 | 36 | 10 | 28 | 5 | 14 | 71 | 30 |
|
| 33 | 46 | 24 | 67 | 23 | 42 | 2 | 6 | 9 | 25 | 71 | 30 |
|
| 30 | 42 | 18 | 50 | 26 | 48 | 5 | 14 | 13 | 36 | 77 | 33 |
|
| 23 | 31 | 12 | 33 | 18 | 33 | 4 | 11 | 2 | 6 | 49 | 21 |
|
| 45 | 63 | 18 | 50 | 28 | 51 | 5 | 14 | 10 | 28 | 91 | 39 |
|
| 32 | 44 | 12 | 33 | 24 | 44 | 2 | 6 | 7 | 19 | 67 | 28 |
|
| 53 | 73 | 14 | 39 | 40 | 74 | 2 | 6 | 1 | 3 | 98 | 42 |
|
| 24 | 33 | 16 | 44 | 23 | 42 | 0 | 0 | 10 | 28 | 59 | 25 |
|
| 42 | 58 | 12 | 33 | 30 | 56 | 8 | 22 | 12 | 33 | 94 | 40 |
| All | 36 (31–47) | 50 (43–66) | 15 (12–20) | 42 (33–54) | 25 (21–30) | 46 (38–56) | 4 (2–7) | 11 (6–19) | 6 (2–9) | 15 (6–25) | 75 (67–92) | 32 (29–39) |
Total scores are presented as median with interquartile range. Scoring is based on Ref 12.
Values are an overall score for all six lung lobes (lingula considered a separate lobe). % scores of each parameter are the percentage of the total score possible.
BE bronchieactasis; MP Mucusplugging; PBT Peribronchial thickening; PAR Parenchymal (ie. opacity and groundglass); EMPH Emphysema (ie. bullous and non-bullous)
a Components scored on a per lobe basis: None, <1/3, 1/3 to 2/3 or >2/3 of the lung lobe (0–3)
b Components scored on a per lobe basis: None, mild, moderate or severe (0–3)
Patient distribution in the histopathologically defined subgroups.
| Emphysema score | ||||
|---|---|---|---|---|
| 0 | 1 | 2 | 3 | |
| Patients, n (%) | 0 (0) | 3 (15) | 15 (75) | 2 (10) |
Emphysema extent was semi-quantitatively scored by two observers in consensus, using a 4-point scale: score 0 (no emphysematous changes); score 1 (0–20% emphysema); score 2 (20–50% emphysema); and score 3 (>50% emphysema). Areas of established fibrosis or bronchiectasis were excluded from the estimation.
Fig 3CT emphysema distribution between the semi-quantitative histopathologic emphysema score subgroups.
CT emphysema is defined as the percentage of lung volume with an attenuation of -950 Houndfield Unit or lower (IN-950).
Fig 4Relation between CT Emphysema extent and age.
CT emphysema is defined as the percentage of lung volume with an attenuation of -950 Houndfield Unit or lower (IN-950).
Correlation between lung function parameters and histopathology and quantified CT emphysema score.
| Histopathology score | CT emphysema (IN-950) | |
|---|---|---|
| FEV1 (%pred) | R = -0.24, p = 0.31 | R = -0.32, p = 0.17 |
| FEV1/FVC (%pred) | R = -0.46, p = 0.04 | R = -0.42, p = 0.07 |
| MEF25–75 (%) | R = -0.54, p = 0.02 | R = -0.42, p = 0.07 |
IN CT emphysema quantified as the percentage of voxels below -950HU in inspiration; FEV Forced expiratory volume in the first second; FEV /FVC ratio of FEV1 over forced vital capacity; MEF Median flow between 25% and 75% of forced vital capacity.